596103-01-4

Upstream product

• 666830-47-3 (2S,3S,4R,5R)-3,4-bis(tert-butyldimethylsilanyloxy)-5-(2-chloro-6-(3-iodobenzylamino)purin-9-yl)-tetrahydro-thiophene-2-carboxylic acid methylamide 
• 696-40-2 3-iodobenzylamine 
• 596103-10-5 benzoic acid (3aS,4R,6R,6aR)-6-(2,6-dichloro-purin-9-yl)-2,2-dimethyl-tetrahydro-thieno[3,4-d][1,3]dioxol-4-ylmethyl ester 
• 666750-34-1 benzoic acid (2R,3S,4R,5R)-5-[2-chloro-6-(3-iodobenzylamino)purin-9-yl]-3,4-dihydroxy-tetrahydro-thiophen-2-yl methyl ester 
• 596103-11-6 benzoic acid (3aS,4R,6R,6aR)-6-(2-chloro-6-(3-iodo-benzylamino)-purin-9-yl)-2,2-dimethyl-tetrahydro-thieno[3,4-d][1,3]dioxol-4-ylmethyl ester 
• 596103-14-9 {(2R,3S,4R,5R)-3,4-bis-(tert-butyl-dimethyl-silanyloxy)-5-[2-chloro-6-(3-iodobenzylamino)-purin-9-yl]-tetrahydro-thiophen-2-yl}-methanol 
• 871913-94-9 (2S,3S,4R,5R)-3,4-Bis-(tert-butyl-dimethyl-silanyloxy)-5-[2-chloro-6-(3-iodo-benzylamino)-purin-9-yl]-tetrahydro-thiophene-2-carboxylic acid 
• 3969-61-7 2,3:5,6-di-O-isopropylidene-D-gulitol 
• 117859-45-7 methanesulfonic acid (S)-((4R)-2,2-dimethyl-[1,3]dioxolan-4-yl)-((4S,5S)-5-methanesulfonyloxymethyl-2,2-dimethyl-[1,3]dioxolan-4-yl)-methyl ester 
• 6322-07-2 D-gulono-1,4-lactone 
• 67642-42-6 2,3,5,6-di-O-isopropylidene-D-gulono-1,4-lactone 
• 666750-24-9 (3aS,4S,6aR)-2,2-dimethyltetrahydrothieno[3,4- d][1,3]dioxole-4-carbaldehyde 
• 596103-06-9 ((3aS,4R,6aR)-2,2- dimethyltetrahydrothieno[3,4-d][1,3]dioxol-4-yl)methanol 
• 596103-05-8 (1R)-1-((3aS,4R,6aR)-2,2-dimethyl-tetrahydro-thieno[3,4-d][1,3]dioxol-4-yl)-ethane-1,2-diol 

Relevant academic research and scientific papers

D-4′-thioadenosine derivatives as highly potent and selective agonists at the human A3 adenosine receptor

4′-Thionucleoside derivatives as potent and selective A3 adenosine receptor agonists were synthesized, starting from D-gulono-γ- lactone via D-thioribosyl acetate as a key intermediate, among which the 2· chloro-N6-methyladenosine-5′

Design, synthesis, and anti-tumor activity of 4′-thionucleosides as potent and selective agonists at the human A3 adenosine receptor

On the basis of potent and selective binding affinity of Cl-IB-MECA to the human A3 adenosine receptor, its 4′-thioadenosine derivatives were efficiently synthesized starting from D-gulonic γ -lactone. Among compounds tested, 2-chloro-N6/

Structure-activity relationships of 2-chloro-N6-substituted- 4′-thioadenosine-5′-uronamides as highly potent and selective agonists at the human A3 adenosine receptor

We have established structure-activity relationships of novel 4′-thionucleoside analogues as the A3 adenosine receptor (AR) agonists. Binding affinity, selectivity toward other AR subtypes, and efficacy in inhibition of adenylate cyclase were studied. Fro

Purine nucleosides

Disclosed are purine nucleoside compounds that are selective to A3 adenosine receptors and are useful for the treatment of cancer and inflammatory diseases. The compounds are shown by the following general formula (I), including isomers thereof: wherein X is sulfur or oxygen; R1 is hydrogen, alkyl, benzyl, halobenzyl, or phenylalkyl; R2 is hydrogen, halogen, alkoxy, alkenyl, alkynyl, alkylthio, or thio; R3 and R3′ are hydrogen, hydroxyalkyl, alkoxycarbonyl, or alkylaminocabonyl, whereas R3 and R3′ do not have identical substituents simultaneously; and R4 is hydrogen or alkyl. Also disclosed are a pharmaceutical composition comprising a compound of formula (I), an isomer, or its pharmacologically acceptable salt as an active ingredient and a method for preventing or treating various diseases, state, or condition, including asthma, inflammation, cerebral ischemia, heart diseases, and cancer.

N6-substituted D-4′-thioadenosine-5′-methyluronamides: Potent and selective agonists at the human A3 adenosine receptor

4′-Thio analogues 3-5 of Cl-IB-MECA (2) (Ki = 1.0 ± 0.2 nM at the human A3 adenosine receptor) were synthesized from D-gulono-γ-lactone via 4-thioribosyl acetate 14 as the key intermediate. All synthesized 4′-thionucleosides exhibite